[go: up one dir, main page]

PE20090895A1 - TRIAZOLE DERIVATIVES AS JAK QUINASE INHIBITORS - Google Patents

TRIAZOLE DERIVATIVES AS JAK QUINASE INHIBITORS

Info

Publication number
PE20090895A1
PE20090895A1 PE2008001287A PE2008001287A PE20090895A1 PE 20090895 A1 PE20090895 A1 PE 20090895A1 PE 2008001287 A PE2008001287 A PE 2008001287A PE 2008001287 A PE2008001287 A PE 2008001287A PE 20090895 A1 PE20090895 A1 PE 20090895A1
Authority
PE
Peru
Prior art keywords
alkyl
pyrazole
alkenyl
methyl
jak
Prior art date
Application number
PE2008001287A
Other languages
Spanish (es)
Inventor
Lynsie Almeida
Brian Aquila
Claudio Edmundo Chuaqui
Huiping Guan
Shan Huang
Stephanos Ioannidis
Michelle Lamb
Bo Peng
Jie Shi
Mei Su
Quibin Su
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40304964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090895(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20090895A1 publication Critical patent/PE20090895A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDO A UN COMPUESTO DERIVADO DE TRIAZOL DE FORMULA (I): DONDE EL ANILLO A ES HETEROCICLILO OPCIONALMENTE SUSTITUIDO SOBRE EL C CON UNO O MAS R2; EL ANILLO B ES SELECCIONADO DE CARBOCICLO Y HETEROCICLILO OPCIONALMENTE SUSTITUIDO SOBRE EL C CON UNO O MAS R4; X ES -O-, -NH- Y -S-; R1 ES HALO, -CN, ALQUILO(C1-C6), ENTRE OTROS; R2 ES -CN, ALQUILO(C1-C6), ALQUENILO(C2-C6), ENTRE OTROS; R3 ES ALQUILO(C1-C6), ALQUENILO(C2-C6); ALQUINILO(C2-C6), ENTRE OTROS; R4 ES ALQUILO(C1-C6), ALQUENILO (C2-C6), CARBOCILILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (S)-N2-(1-(5-FLUOROPIRIDIN-2-IL)ETIL)-N4-(5-METIL-1H-PIRAZOL-3-IL)-6-(4-METILPIPERAZIN-1-IL)-1,3,5-TRIAZINA-2,4-DIAMINA, (S)-N2-(1-(5-FLUOROPIRIMIDIN-2-IL)ETIL)N4-(5-METIL-1H-PIRAZOL-3-IL)-6-MORFOLIN-1,3,5-TRIAZINA-2,4-DIAMINA, 4-(1-(5-FLUOROPIRIDIN-2-IL)ETOXI)-N-(5-METIL-1H-PIRAZOL-3-IL)-6-MORFOLIN-1,3,5-TRIAZIN-2-AMINA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA FORMULACION Y A UN METODO DE PREPARACION. DICHO COMPUESTO TIENE ACTIVIDAD INHIBITORIA DE JAK QUINASA Y ES UTIL EN EL TRATAMIENTO DE TRASTORNOS MIELOPROLIFERATIVOS Y EL CANCERREFERRING TO A COMPOUND DERIVED FROM TRIAZOLE OF FORMULA (I): WHERE THE RING A IS HETEROCYCLYL OPTIONALLY SUBSTITUTED ON THE C WITH ONE OR MORE R2; RING B IS SELECTED FROM CARBOCYCLE AND HETEROCYCLYL OPTIONALLY SUBSTITUTED ON C WITH ONE OR MORE R4; X IS -O-, -NH- AND -S-; R1 IS HALO, -CN, (C1-C6) ALKYL, AMONG OTHERS; R2 IS -CN, ALKYL (C1-C6), ALKENYL (C2-C6), AMONG OTHERS; R3 IS ALKYL (C1-C6), ALKENYL (C2-C6); ALKINYL (C2-C6), AMONG OTHERS; R4 IS ALKYL (C1-C6), ALKENYL (C2-C6), CARBOCILYL, AMONG OTHERS. PREFERRED COMPOUNDS ARE: (S) -N2- (1- (5-FLUOROPYRIDIN-2-IL) ETHYL) -N4- (5-METHYL-1H-PYRAZOLE-3-IL) -6- (4-METHYLPIPERAZIN-1- IL) -1,3,5-TRIAZINE-2,4-DIAMINE, (S) -N2- (1- (5-FLUOROPYRIMIDIN-2-IL) ETHYL) N4- (5-METHYL-1H-PYRAZOLE-3- IL) -6-MORPHOLIN-1,3,5-TRIAZINE-2,4-DIAMINE, 4- (1- (5-FLUOROPYRIDIN-2-IL) ETHOXY) -N- (5-METHYL-1H-PYRAZOLE-3 -IL) -6-MORFOLIN-1,3,5-TRIAZIN-2-AMINE, AMONG OTHERS. IT ALSO REFERS TO A FORMULATION AND A METHOD OF PREPARATION. SAID COMPOUND HAS JAK KINASE INHIBITORY ACTIVITY AND IS USEFUL IN THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS AND CANCER

PE2008001287A 2007-07-31 2008-07-31 TRIAZOLE DERIVATIVES AS JAK QUINASE INHIBITORS PE20090895A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95315807P 2007-07-31 2007-07-31

Publications (1)

Publication Number Publication Date
PE20090895A1 true PE20090895A1 (en) 2009-08-08

Family

ID=40304964

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001287A PE20090895A1 (en) 2007-07-31 2008-07-31 TRIAZOLE DERIVATIVES AS JAK QUINASE INHIBITORS

Country Status (6)

Country Link
AR (1) AR069899A1 (en)
CL (1) CL2008002243A1 (en)
PE (1) PE20090895A1 (en)
TW (1) TW200906818A (en)
UY (1) UY31254A1 (en)
WO (1) WO2009016410A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108524505A (en) 2009-03-13 2018-09-14 安吉奥斯医药品有限公司 Method and composition for cell Proliferation associated disease
AU2010259002B2 (en) * 2009-06-08 2014-03-20 Nantbio, Inc. Triazine derivatives and their therapeutical applications
JP2012529517A (en) * 2009-06-09 2012-11-22 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー Benzyl-substituted triazine derivatives and their therapeutic applications
NZ622505A (en) 2009-06-29 2015-12-24 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
CA2793835C (en) 2009-10-21 2021-07-20 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
PT2704721T (en) 2011-05-03 2018-06-14 Agios Pharmaceuticals Inc Pyruvate kinase activators for use in therapy
CN102827073A (en) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 Therapeutically active compositions and application methods thereof
CN102827170A (en) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 Active treatment compositions and use method thereof
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
AR091858A1 (en) * 2012-07-25 2015-03-04 Sova Pharmaceuticals Inc CISTATIONIN-g-LIASA INHIBITORS (CSE)
MX365747B (en) 2012-10-15 2019-06-12 Agios Pharmaceuticals Inc Therapeutic compounds and compositions.
CN105517996B (en) * 2013-07-11 2019-03-26 安吉奥斯医药品有限公司 Therapeutic active compounds and methods of use
US10376510B2 (en) 2013-07-11 2019-08-13 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
NZ723859A (en) 2014-03-14 2023-01-27 Servier Lab Pharmaceutical compositions of therapeutically active compounds and their uses
DK3245190T3 (en) 2015-01-16 2019-02-18 Bayer Cropscience Ag METHOD FOR PREPARING 4-CYANOPIPERIDE HYDROCHLORIDE
RS64777B1 (en) 2015-06-11 2023-11-30 Agios Pharmaceuticals Inc Methods of using pyruvate kinase activators
HRP20211790T1 (en) 2015-10-15 2022-03-04 Les Laboratoires Servier Combination therapy for treating malignancies
FI3362065T3 (en) 2015-10-15 2024-06-19 Servier Lab Combination therapy comprising ivosidenib, cytarabine and daunorubicin or idarubicin for treating acute myelogenous leukemia
WO2019046316A1 (en) * 2017-08-28 2019-03-07 Acurastem Inc. Pikfyve kinase inhibitors
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CA3103624A1 (en) * 2018-06-22 2019-12-26 Aduro Biotech, Inc. Triazine compounds and uses thereof
CN109020951B (en) * 2018-08-24 2020-06-02 大连理工大学 Naphthalimide derivatives containing trisubstituted cyanuric chloride and their synthesis methods and applications
WO2021062163A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
AU2021207804A1 (en) 2020-01-13 2022-09-01 Verge Analytics, Inc. Substituted pyrazolo-pyrimidines and uses thereof
CA3177830A1 (en) 2020-05-13 2021-11-18 Maria BECONI Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
CN111454214B (en) * 2020-05-27 2023-04-07 龙曦宁（上海）医药科技有限公司 Synthetic method of 2-methoxy-1-pyrimidineethylamine hydrochloride

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1317450B1 (en) * 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2432222C (en) * 2000-12-21 2008-07-29 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7179826B2 (en) * 2002-03-15 2007-02-20 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
JP2008540622A (en) * 2005-05-16 2008-11-20 アストラゼネカ アクチボラグ Compound
EP1945631B8 (en) * 2005-10-28 2013-01-02 AstraZeneca AB 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer

Also Published As

Publication number Publication date
AR069899A1 (en) 2010-03-03
UY31254A1 (en) 2009-04-30
TW200906818A (en) 2009-02-16
WO2009016410A2 (en) 2009-02-05
CL2008002243A1 (en) 2009-08-21
WO2009016410A3 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
PE20090895A1 (en) TRIAZOLE DERIVATIVES AS JAK QUINASE INHIBITORS
PE20090773A1 (en) DERIVATIVES OF MORPHOLINE PYRIMIDINE
PE20081362A1 (en) MORPHOLINO PYRIMIDINE DERIVATIVES AS INHIBITORS OF mTOR KINASE AND PI3K
PE20141681A1 (en) BTK INHIBITORS
PE20140934A1 (en) DERIVATIVES OF PIRAZOLE
PE20150621A1 (en) DERIVATIVES OF 2,4-DIAMINE-PYRIMIDINE N2, N4-DISUSTITUTED AS JAK3 INHIBITORS
PE20161066A1 (en) PIPERIDINYL-INDOLE DERIVATIVES AS INHIBITORS OF COMPLEMENT FACTOR B AND USES OF THE SAME
PE20091573A1 (en) HETEROCYCLIC DERIVATIVES OF UREA AS INHIBITORS OF DNA GIRASE AND / OR TOPOISOMERASE
PE20131377A1 (en) TRIAZINE-OXADIAZOLES
PE20100138A1 (en) MORPHOLIN PYRIMIDINE DERIVATIVES USED IN MTOR KINASE AND / OR PI3K-RELATED DISEASES
PE20090210A1 (en) COMPOUNDS DERIVED FROM PYRAZOLO PYRIMIDINE AS INHIBITORS OF JAK QUINASE
PE20081845A1 (en) NEW AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS
PE20070808A1 (en) COMPOUNDS DERIVED FROM ISOQUINOLINE AS INHIBITORS OF Rho-KINASE
NO20080675L (en) P38-Map kinase inhibitors and methods for their use
PE20130385A1 (en) DERIVATIVES OF NAFT-2-ILACETIC ACID TO TREAT AIDS
PE20050681A1 (en) PYRID [2,3-d] PYRIMIDINE-2,4-DIAMINES AS INHIBITORS OF PDE 2
PE20090887A1 (en) DERIVATIVES OF 1H-PYRAZOLE- [3,4-d] -PYRIMIDINE, 9H-PURINE AND 7H-PYRROL- [2,3-d] -PYRIMIDINE AS KINASE INHIBITORS P70 S6
NZ591449A (en) Picolinamide derivatives as kinase inhibitors
PE20161236A1 (en) TRIAZINE COMPOUND AND ITS USE FOR MEDICAL PURPOSES
PE20100087A1 (en) COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS
AR059957A1 (en) DERIVATIVES OF SPIROINDOLINONE, METHODS FOR THEIR PREPARATION, A PHARMACEUTICAL COMPOSITION CONTAINING THEM AND THEIR USE IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF CANCER.
PE20090816A1 (en) PYRROLOPYRIMIDINONE DERIVATIVES AS BINDING AGENTS OF P2X3 RECEPTORS
PE20081393A1 (en) QUINOLINE DERIVATIVES AS INHIBITORS OF CSF-1R
CL2012001366A1 (en) Carboxamida
PE20110433A1 (en) ANTAGONISTS OF THE DISUSTITUTED PHTHALAZINE HEDGEHOG PATHWAY

Legal Events

Date Code Title Description
FD Application declared void or lapsed